Drug Profile
Cendakimab - Celgene Corporation
Alternative Names: ABT-308; CC 93538; RPC 4046Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer AbbVie; Celgene Corporation
- Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Eosinophilic gastroenteritis; Eosinophilic oesophagitis
- Phase II Atopic dermatitis; Systemic lupus erythematosus
- Discontinued Asthma
Most Recent Events
- 14 Oct 2023 Pharmacodynamics and efficacy data from the phase II HEROES trial in Eosinophilic oesophagitis presented at the 31st United European Gastroenterology week (UEG-2023)
- 27 Jun 2023 Bristol-Myers Squibb completes the phase I trial in Healthy volunteers (SC) in China (NCT05638282)
- 15 Feb 2023 Bristol-Myers Squibb initiates the phase I trial in Healthy volunteers (SC) in China (NCT05638282)